In SURMOUNT-5, gastrointestinal adverse events were the most common with both medications and were generally mild to moderate
Clinically diagnosed gastroparesis in GLP-1 users appears uncommon, though precise incidence rates are difficult to establish
These receptors are primarily in the gastrointestinal system, but they're also in the brain and small amounts in the heart
People try calorie restriction, exercise programmes, and older appetite suppressants, but the results are often limited and do not last
If the clinician determines Microdose isn't right for you, they may recommend a different protocol your monthly billing only changes if your clinician switches you to a different compound
Imagine Retatrutide is a Ferrari engine